Biofit of Louisiana

Biofit of Louisiana operates as a medical weight loss clinic in Baton Rouge, LA, under the clinical direction of Mary Holden Jones, MD, FAAP, a board-certified pediatrician who has expanded her practice to address metabolic health and obesity management in adults. The clinic focuses exclusively on evidence-based pharmacotherapy for weight management, utilizing GLP-1 receptor agonists as the cornerstone of its treatment protocols. Dr. Jones brings her background in pediatric medicine and family health to adult weight management, emphasizing metabolic optimization and sustainable lifestyle modification alongside pharmaceutical intervention.

The clinic's treatment menu centers on two FDA-approved incretin mimetics: Semaglutide and Tirzepatide. Semaglutide, a GLP-1 receptor agonist, is administered as a once-weekly subcutaneous injection that works by slowing gastric emptying, reducing appetite, and improving glycemic control in patients with or without type 2 diabetes. Tirzepatide represents a dual GIP/GLP-1 receptor agonist mechanism, targeting both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways to enhance weight reduction outcomes. Biofit of Louisiana provides these medications through individualized dosing protocols that begin at lower therapeutic levels and titrate upward based on patient tolerance and response. Dr. Jones conducts initial medical evaluations to assess candidacy, reviewing cardiovascular history, thyroid function, and contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Patients at Biofit of Louisiana receive in-person consultations at the Baton Rouge clinic location, where Dr. Jones performs comprehensive metabolic assessments including body composition analysis, review of comorbid conditions such as hypertension or dyslipidemia, and discussion of realistic weight loss expectations. The clinic does not offer telehealth services, requiring all patients to attend face-to-face appointments for medication initiation, follow-up monitoring, and dose adjustments. This in-person model allows Dr. Jones to directly assess injection technique, monitor for adverse effects such as gastrointestinal symptoms or gallbladder complications, and provide hands-on guidance for patients new to self-administered peptide therapy. Follow-up visits typically occur every four weeks during the titration phase, with extended intervals once patients reach maintenance dosing.

The clinical approach at Biofit of Louisiana integrates pharmacotherapy with nutritional counseling and behavioral modification strategies, recognizing that GLP-1 and GIP agonists function most effectively when combined with caloric restriction and increased physical activity. Dr. Jones provides patients with structured meal planning resources, macronutrient targets appropriate for their metabolic profile, and strategies to manage the appetite suppression effects of these peptides without compromising nutritional adequacy. The clinic monitors patients for common side effects including nausea, constipation, and injection site reactions, adjusting protocols as needed to optimize tolerability. Patients with a history of disordered eating or those taking medications that affect gastric motility receive additional screening to ensure safe co-administration.

Biofit of Louisiana serves the greater Baton Rouge area and surrounding Louisiana parishes, providing a medically supervised alternative to commercial weight loss programs for patients who meet clinical criteria for pharmacologic intervention. The clinic accepts patients with a body mass index of 30 or greater, or those with a BMI of 27 or above with at least one weight-related comorbidity such as prediabetes, obstructive sleep apnea, or cardiovascular disease. Dr. Jones maintains hospital privileges and coordinates care with patients' primary care physicians and endocrinologists when appropriate, ensuring continuity across the healthcare spectrum. The clinic's focus on two specific peptide therapies allows for deep clinical expertise in managing these agents, troubleshooting challenges, and maximizing patient outcomes within a defined scope of practice.